Hosted on MSN1mon
Hansa Biopharma sees 2025 growth through expanded IDEFIRIX adoption and new market reimbursementsHansa Biopharma delivered strong full-year sales ... With expanded reimbursement, the completion of critical trials, and growing market penetration, the company is optimistic about achieving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results